ClinicalTrials.gg
Active, not recruitingNCT04797299ELISAUpdated Oct 5, 2026

Prospective Evaluation of Breast-Conserving Surgery Alone in Low-Risk Ductal Carcinoma in Situ (DCIS)

An observational study in DCIS, sponsored by Ontario Clinical Oncology Group (OCOG). Active, not recruiting at 24 sites in Canada. Open to female participants aged 46 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Ontario Clinical Oncology Group (OCOG) · Observational

How we know

Updated Oct 5, 2026Now Active, not recruiting1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
526
Ages
46 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Carcinoma, Intraductal, Noninfiltrating with a site in Canada — 1 open to participants now, 5 under way, 3 of them phase 3. Carcinoma, Intraductal, Noninfiltrating · Canada.

Started
2022
the only one that year
Observational
2 of 19
none open now
Registered
19th of 19
by date
Lead sponsor
4 of 19
Ontario Clinical Oncology Group (OCOG)

Among the 19 studies in Carcinoma, Intraductal, Noninfiltrating with a site in Canada, this one is the only one that started in 2022, is one of 2 observational ones, and was the 19th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

1 of the 19 studies in Carcinoma, Intraductal, Noninfiltrating with a site in Canada is open now. Recruiting first, the newest first:

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 46 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Carcinoma, Intraductal, Noninfiltrating with a site in Canada, or all of them as a file.
02

Study summary

To evaluate whether the combination of clinicopathological factors and the use of the Oncotype DX DCIS score can avoid radiation in women with low risk DCIS who have had breast conserving surgery (BCS)

Read the detailed description

A prospective cohort study, conducted in Canada, to prospectively evaluate whether the combination of clinicopathological criteria and the Oncotype DX DCIS score can identify a group of women at very low risk of local recurrence following breast conserving surgery who do not require breast radiation therapy. We plan to screen 809 consenting women who will have their tumour tissue specimen sent to Exact Sciences to assess their DCIS score. We anticipate that 526 women will have an Oncotype DX DCIS score with a predicted 10-year risk of local recurrence ≤10%, these women will be enrolled and followed as part of the study.

At each centre, all patients with DCIS referred to radiation oncology will be documented. When a physician identifies an eligible patient, the patient will be approached by the referring physician or delegate to voluntarily provide informed consent to participate in this study. Consenting patients will be registered through the Ontario Clinical Oncology Group's (OCOG) web-based registration system. A two-step registration/enrollment process will be implemented.

Data related to the patient demographics, surgery details, tumour characteristics and ECOG performance will be collected. The patient's tumour specimen will be sent for analysis to Exact Sciences. The DCIS score results will be sent to the referring physician. OCOG will also receive the DCIS score results. Patients will be followed yearly up to 10 years. Bilateral mammograms and breast exams will be performed annually. The study data will be verified by source documentation.

03

Conditions studied

  • DCIS

Keywords

  • Ductal Carcinoma in Situ
  • Breast Conserving Surgery
  • Oncotype DX DS
04

Who can participate

Ages eligible
46 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Prospective cohort study conducted in Canada in women with a low risk DCIS following breast conserving surgery who are candidates for radiation.

Eligibility status should be confirmed by the referring physician or delegate prior to enrollment. It is important that no exceptions are made to the eligibility criteria. Questions related to eligibility requirements and/or specific criteria should be addressed with OCOG prior to enrollment

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patient > 45 years of age with DCIS without microinvasion.
  2. Tumour size ≤ 2.5cm.
  3. Treated by BCS with clear resection margins ≥ 2 mm or no residual disease on re-excision.*

    * Patients with anterior margins and posterior margins ≥1 mm are eligible. Or if the dissection was confirmed to be taken to skin and down to fascia with no DCIS present at inked margins.

  4. Oncotype DX DCIS score with a predicted 10-year risk of LR ≤10%.

Exclusion criteria

Exclusion Criteria:

  1. Multifocal DCIS.
  2. History of any invasive breast cancer or non-invasive breast cancer in the ipsilateral breast.
  3. Synchronous or previous invasive or non-invasive breast cancer.
  4. Prior history of invasive cancer within the last 5 years, excluding non-melanoma skin cancers.
  5. performance status ≥3.
  6. \<10 years.
  7. Geographic inaccessibility for follow-up.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
526 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Single Arm Cohort

    Evaluating the risk of Local Recurrence (LR) in a group of women postulated to be at low risk of LR following Breast Conserving Surgery alone defined by a combination of clinicopathological factors and Oncotype DX DCIS score.

06

What researchers measure

Primary outcomes

  1. Ipsilateral local recurrence (LR)

    Defined as recurrent invasive or in situ cancer in the ipsilateral breast

    Time frame: 5 Year

Secondary outcomes

  1. Ipsilateral invasive local recurrence

    defined as time from study registration to time of recurrent invasive cancer in the ipsilateral breast

    Time frame: 5 Year

  2. Breast cancer recurrence-free interval (RFI)

    defined as time from study registration to time of documented recurrent disease (ipsilateral breast (DCIS or invasive), regional, distant or death from breast cancer

    Time frame: 5 Year

  3. Distant disease-free survival (DDFS)

    defined as time from study registration to distant recurrence

    Time frame: 5 Year

  4. Disease-free survival (DFS)

    defined as time from registration to time of LR (DCIS or invasive), regional and distant recurrence, contralateral breast cancer, new primary (non-breast) and death from any cause

    Time frame: 5 Year

  5. Overall survival (OS)

    defined as time from registration to death of any cause

    Time frame: 5 Year

07

Study locations

24 sites
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2022 (actual). Primary completion is estimated for Nov 2030, 96 months after the start.

Of 28 non-industry observational studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 86. This study's planned 96 months is above that.

Counting every sponsor, half of 30 studies reached it within 60 months; a quarter within 46 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 15, 2021
StartActual
Nov 23, 2022
Primary completionEst.
Nov 30, 2030
CompletionEst.
Nov 30, 2035
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 5, 2026
Sites
1 site removed
Show 1 removed
  • Jewish General Hospital · Montreal, Canada
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Recruiting→Active, not recruiting
    1 site removed
    Show 1 removed
    • Jewish General Hospital · Montreal, Canada
    + 1 other change: contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04797299
Lead sponsor
Ontario Clinical Oncology Group (OCOG)
Collaborators
Canadian Institutes of Health Research (CIHR), Hamilton Health Sciences Corporation
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Nov 23, 2022
Primary completion
Nov 30, 2030 (estimated)
Completion
Nov 30, 2035 (estimated)
Last update
Oct 5, 2026

Study contacts

Eileen Rakovitch, M.D.
principal investigator · Sunnybrook Research Institute, Sunnybrook Health Science
Tim Whelan, M.D
principal investigator · Juravinski Cancer Centre

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion